Effects of a novel Nodal-targeting monoclonal antibody in melanoma(450 views)(PDF restricted223 views) Strizzi L, Sandomenico A, Margaryan NV, Foca A, Sanguigno L, Bodenstine TM, Chandler GS, Reed DW, Gilgur A, Seftor EA, Seftor RE, Khalkhali-ellis Z, Leonardi A, Ruvo M, Hendrix MJ
Oncotarget (ISSN: 1949-2553, 1949-2553electronic), 2015 Oct 27; 6(33): 34071-34086.
1 Cancer Biology and Epigenomics Program, Stanley Manne Children’s Research Institute, Ann and Robert H. Lurie Children’s
2 Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
3 Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
4 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
5 Istituto di Biostrutture e Bioimmagini del CNR and CIRPeB, Università Federico II di Napoli, Naples, Italy
6 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II di Napoli, Naples, Italy
* These authors have contributed equally to this work
References: Not available.
Effects of a novel Nodal-targeting monoclonal antibody in melanoma
Nodal is highly expressed in various human malignancies, thus supporting the
rationale for exploring Nodal as a therapeutic target. Here, we describe the effects
of a novel monoclonal antibody (mAb), 3D1, raised against human Nodal. In vitro
treatment of C8161 human melanoma cells with 3D1 mAb shows reductions in
anchorage-independent growth and vasculogenic network formation. 3D1 treated
cells also show decreases of Nodal and downstream signaling molecules, P-Smad2
and P-ERK and of P-H3 and CyclinB1, with an increase in p27. Similar effects were
previously reported in human breast cancer cells where Nodal expression was
generally down-regulated; following 3D1 mAb treatment, both Nodal and P-H3 levels
are reduced. Noteworthy is the reduced growth of human melanoma xenografts in
Nude mice treated with 3D1 mAb, where immunostaining of representative tumor
sections show diminished P-Smad2 expression. Similar effects both in vitro and in
vivo were observed in 3D1 treated A375SM melanoma cells harboring the active
BRAF(V600E) mutation compared to treatments with IgG control or a BRAF inhibitor,
dabrafenib. Finally, we describe a 3D1-based ELISA for the detection of Nodal in
serum samples from cancer patients. These data suggest the potential of 3D1 mAb
for selecting and targeting Nodal expressing cancers.
Effects of a novel Nodal-targeting monoclonal antibody in melanoma
Schutz K, Alecsandru D, Grimbacher B, Haddock J, Bruining A, Driessen G, De Vries E, Van Hagen PM, Hartmann I, Fraioli F, Milito C, Mitrevski M, Quinti I, Serra G, Kelleher P, Loebinger M, Litzman J, Postranecka V, Thon V, Babar J, Condliffe AM, Exley A, Kumararatne D, Screaton N, Jones A, Bondioni MP, Lougaris V, Plebani A, Soresina A, Sirignano C, Spadaro G, Galal N, Gonzalez-granado LI, Dettmer S, Stirling R, Chapel H, Lucas M, Patel S, Farber CM, Meyts I, Banerjee AK, Hackett S, Hurst JR, Warnatz K, Gathmann B, Weidemann J, Berthold D, Baumann U * Correction to: Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group(223 views)(PDF 13 views) J Clin Immunol (ISSN: 0271-9142linking, 1573-2592), 2019 Feb; 39(2): 225-227. Impact Factor:2.654 ViewExport to BibTeXExport to EndNote
Schutz K, Alecsandru D, Grimbacher B, Haddock J, Bruining A, Driessen G, De Vries E, Van Hagen PM, Hartmann I, Fraioli F, Milito C, Mitrevski M, Quinti I, Serra G, Kelleher P, Loebinger M, Litzman J, Postranecka V, Thon V, Babar J, Condliffe AM, Exley A, Kumararatne D, Screaton N, Jones A, Bondioni MP, Lougaris V, Plebani A, Soresina A, Sirignano C, Spadaro G, Galal N, Gonzalez-granado LI, Dettmer S, Stirling R, Chapel H, Lucas M, Patel S, Farber CM, Meyts I, Banerjee AK, Hackett S, Hurst JR, Warnatz K, Gathmann B, Weidemann J, Berthold D, Baumann U, Schutz K, Alecsandru D, Grimbacher B, Haddock J, Bruining A, Driessen G, De Vries E, Van Hagen PM, Hartmann I, Fraioli F, Milito C, Mitrevski M, Quinti I, Serra G, Kelleher P, Loebinger M, Litzman J, Postranecka V, Thon V, Babar J, Condliffe AM, Exley A, Kumararatne D, Screaton N, Jones A, Bondioni MP, Lougaris V, Plebani A, Soresina A, Sirignano C, Spadaro G, Galal N, Gonzalez-granado LI, Dettmer S, Stirling R, Chapel H, Lucas M, Patel S, Farber CM, Meyts I, B * Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group(200 views)(PDF 18 views) J Clin Immunol (ISSN: 0271-9142linking, 1573-2592), 2019 Jan; 3939(2): 45-54. Impact Factor:2.654 ViewExport to BibTeXExport to EndNote